Global Hemoglobin A1C (HbA1C) Testing Market to Reach US$2.3 Billion by 2030

The global market for Hemoglobin A1C (HbA1C) Testing estimated at US$1.3 Billion in the year 2023, is expected to reach US$2.3 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2023-2030. Ion-Exchange High Performance Liquid Chromatography (HPLC), one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$915.7 Million by the end of the analysis period. Growth in the Immunoassays segment is estimated at 9.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$386.6 Million While China is Forecast to Grow at 10.6% CAGR

The Hemoglobin A1C (HbA1C) Testing market in the U.S. is estimated at US$386.6 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$274.2 Million by the year 2030 trailing a CAGR of 10.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.5% and 8.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.9% CAGR.

Global Hemoglobin A1C (HbA1c) Testing Market - Key Trends & Drivers Summarized

Hemoglobin A1C (HbA1c) testing is a crucial diagnostic tool for managing diabetes, providing a long-term indicator of blood glucose levels over the past two to three months. Unlike regular blood glucose tests that measure a snapshot of current blood sugar levels, HbA1c tests reflect the average blood glucose levels by measuring the percentage of glycated hemoglobin in the blood. This test is essential for diagnosing diabetes, assessing the effectiveness of treatment plans, and making necessary adjustments to medication or lifestyle. It helps healthcare providers and patients monitor glycemic control more effectively, thereby reducing the risk of diabetes-related complications.

The importance of HbA1c testing in diabetes management cannot be overstated, as it provides comprehensive insights into how well a patient`s blood sugar levels are being managed over time. The test is typically recommended every three to six months for individuals with diabetes, but it is also used for screening and diagnosing prediabetes and diabetes in the general population. Advances in testing technology have made HbA1c tests more accurate, accessible, and convenient, with point-of-care testing devices enabling quicker results in clinical settings. Additionally, home testing kits have become available, empowering patients to monitor their condition more proactively.

The growth in the Hemoglobin A1C (HbA1c) testing market is driven by several factors. Firstly, the rising prevalence of diabetes worldwide is increasing the demand for regular HbA1c testing to manage and diagnose the condition effectively. Secondly, advancements in diagnostic technology are making HbA1c tests more accurate and accessible, enhancing their adoption in both clinical and home settings. Thirdly, the growing emphasis on preventive healthcare and early diagnosis of diabetes is driving the market for HbA1c testing as a key component of diabetes management programs. Lastly, increasing awareness and education about diabetes and its complications are encouraging more frequent and consistent testing among at-risk populations. These factors collectively ensure the continued growth and importance of the HbA1c testing market.